Replies to post #229405 on Cytodyn Inc (CYDY)

[justdafactss]

FDA said--- With the conclusion of both the CD10 and CD12 clinical trials, it has become clear that the data currently available do not support the clinical benefit of leronlimab for the treatment of COVID-19. In the smaller study that CytoDyn conducted in patients with mild-to-moderate COVID-19 disease (CD10), there was no observed effect of the drug on the study’s primary endpoint or on any of the secondary endpoints.
https://www.fda.gov/drugs/drug-safety-and-availability/statement-leronlimab

Hmmm....Proactive video says 'Strong results', FDA says "there was no observed effect of the drug on the study’s primary endpoint or on any of the secondary endpoints."

Whos telling the truth and who aint?